Nizatidine: Difference between revisions
Activating IUPHAR link. Report errors and suggestions to User_talk:BogBot |
m Infobox drug: rm/replace deprecated params. Fix unk parameters (rm some Chembox-params) (via AWB script) |
||
Line 4:
| IUPAC_name = ''N''-(2-[(2-[(dimethylamino)methyl]thiazol-4-yl)methylthio]ethyl)-''N''-methyl-2-nitroethene-1,1-diamine
| image = Nizatidine structure.png
<!--Clinical data-->
| tradename = Axid
Line 16 ⟶ 15:
| legal_US _comment = and OTC<ref name=LiverTox/>
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = >70%
Line 23 ⟶ 21:
| elimination_half-life = 1-2 hours
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| IUPHAR_ligand = 7248
Line 33 ⟶ 30:
| PubChem = 3033637
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2298266
Line 44 ⟶ 41:
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 653
<!--Chemical data-->
| C=12 | H=21 | N=5 | O=2 | S=2
| molecular_weight = 331.46 g/mol
| smiles = [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C
|
Revision as of 12:48, 28 June 2015
Clinical data | |
---|---|
Trade names | Axid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a694030 |
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >70% |
Protein binding | 35% |
Metabolism | Hepatic |
Elimination half-life | 1-2 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.155.683 |
Chemical and physical data | |
Formula | C12H21N5O2S2 |
Molar mass | 331.46 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
Clinical use
Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD), and to prevent stress ulcers.[1]
Adverse effects
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. [2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). [3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[4]
Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.
See also
- Famotidine, Pepcid AC, Pepcidine: another popular H2-receptor antagonist
References
- ^ a b c U.S. National Library of Medicine Last updated: 4 November 2014 LiverTox Database: Nizatidine
- ^ Eli Lilly and Company and Reliant Pharmaceuticals Announce
- ^ Reliant Pharmaceuticals : Press Releases
- ^ Reliant Pharmaceuticals : Press Releases